



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

Date: 29.05.2024

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Submission of Audited Financial Results for the Quarter and Year ended on March 31, 2024 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. May 29, 2024, inter alia, considered and approved followings:

1. Audited Financial Results for the quarter and financial year ended March 31, 2024 along with Auditor's Report.

A copy of the Audited Financial Results of the Company for the quarter and year ended March 31, 2024 along with statements of Assets & Liabilities, Cash Flow Statement, Auditors' Report and declaration on Audit Reports with unmodified opinion are enclosed herewith.

2. Approved the re-appointment of M/s Vijay Bhatt & Co., Practicing Company Secretaries, as Secretarial Auditor of the company for the financial year 2024-25.
3. Approved the re-appointment of, Dipak Rajpara & Co., Chartered Accountants, as the Internal Auditors of the Company for the financial year 2024-25.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



The disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 for re-appointment of Secretarial Auditor and Internal Auditor are enclosed herewith Annexure.

The meeting of the Board of Directors commenced at 12:00 noon and concluded at 15:45 p.m.

Kindly take the same on your record.

Thanking you,

Yours truly,
For Link Pharma Chem Limited

Khushbu Patel
Company Secretary
Membership No.: A65182

Encl: As above.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LIMITED
CIN : L24230GJ1984PLC007540

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2024

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended	
		31st March 2024	31st December 2023	31st March 2023	31st March 2024	31st March 2023
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	803.24	793.92	929.14	2,989.77	3,875.78
	Other income	(1.05)	36.97	(2.50)	64.03	(14.73)
	Total Income (A)	802.19	830.90	926.64	3,053.80	3,861.05
2	Expenses:					
	Cost of materials consumed	473.76	396.38	719.24	1,436.95	2,640.87
	Changes in inventories of finished goods and work-in-progress	(95.14)	(12.89)	(190.01)	231.14	(504.34)
	Employee benefits expense	141.91	145.00	134.53	551.61	568.87
	Finance costs	19.48	23.06	25.97	87.20	76.10
	Depreciation and amortization expense	24.92	26.61	23.03	103.42	92.28
	Other Expenses	190.71	237.54	237.28	835.05	898.63
	Total expenses (B)	755.64	815.70	950.04	3,245.37	3,772.41
3	(Loss)/Profit before tax (C) = (A-B)	46.55	15.20	(23.41)	(191.57)	88.63
4	Tax expense:					
	(1) Current tax	-	-	0.72	-	41.50
	(2) Short/(Excess) Provision of tax relating to earlier Year	-	-	-	0.63	-
	(3) Deferred tax	20.55	(6.92)	(4.78)	(55.92)	(18.28)
	Total tax expense (D)	20.55	(6.92)	(4.06)	(55.29)	23.22
5	(Loss)/Profit for the year/period (E) = (C-D)	26.00	22.12	(19.34)	(136.29)	65.42
6	Other Comprehensive Income					
	Items that will not be reclassified to profit or loss					
	Net fair value gain on equity instruments through Other Comprehensive Income	0.04	0.14	(0.07)	0.38	(0.06)
	Remeasurement (loss) / gain of the defined benefit plan	15.34	(3.75)	(16.33)	4.09	(12.42)
	Income tax effect on above	(4.07)	0.94	4.56	(1.22)	3.47
	Total other comprehensive income for the year/period, net of tax (F)	11.31	(2.67)	(11.84)	3.25	(9.01)
7	Total comprehensive income for the year/period (Net of Tax) (E+F)	37.31	19.45	(31.18)	(133.04)	56.41
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06
9	Other Equity				926.81	1,059.85
10	Earnings per equity share (FV of Rs. 10) (Rs.) Basic and Diluted	0.59	0.50	(0.44)	(3.07)	1.47



REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

Website : www.linkpharmalchem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

Notes:

- 1 The above financial results for the quarter and year ended on March 31, 2024 have been audited by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on May 29th, 2024.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 - 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

Particulars	Quarter ended			Year ended	
	31st March 2024	31st December 2023	31st March 2023	31st March 2024	31st March 2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Other income (A)	(1.05)	36.97	(2.50)	64.03	(14.73)
Net Gain/(loss) arising on financial asset designated as at FVTPL (B)	(10.07)	37.12	(19.08)	49.21	(40.69)
Adjusted Other Income (A-B)	9.02	(0.15)	16.58	14.82	25.96

- 4 The statement of financial results includes the result for the year ended March 31, 2024, being the balancing figures between the audited figures in respect of full financial year ended March 31, 2024 and published unaudited year to date figures up to the 3rd quarter of the current financial year, which were subjected to a limited review, as required under the listings regulations

Date : May 29th, 2024
Place : Vadodara



For Link Pharma Chem Limited

Satish G. Thakur
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

Website: www.linkpharmachem.co.in CIN: L242306171984PLC007540



Link

Pharma Chem Ltd.

LINK PHARMA CHEM LIMITED
CIN : L24230GJ1984PLC007540

ISO-9001 - 2015 - ISO-14001 - 2015

STATEMENT OF ASSETS AND LIABILITIES

(Rs in Lakhs)

Particulars	As at 31st March, 2024	As at 31st March, 2023
	(Audited)	(Audited)
I. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	993.71	900.29
(b) Financial Assets		
(i) Investments	293.28	363.87
(ii) Other financial assets	129.02	116.19
(c) Other non-current assets	26.42	110.51
Total non-current assets	1,442.43	1,490.86
2. CURRENT ASSETS		
(a) Inventories	620.80	1,225.00
(b) Financial Assets		
(i) Trade receivables	515.16	362.99
(ii) Cash and cash equivalents	6.42	9.39
(iii) Bank Balances other than (ii) above	2.52	10.42
(iv) Loans	1.25	7.20
(v) Other financial assets	-	1.77
(c) Other current assets	6.45	138.17
Total current assets	1,152.60	1,754.94
Total Assets	2,595.03	3,245.80
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	444.06	444.06
(b) Other Equity	926.81	1,059.85
Total Equity	1,370.87	1,503.91
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
Borrowings	105.83	198.01
(b) Provisions	0.23	20.15
(c) Deferred tax liabilities (Net)	17.60	72.29
Total non-current liabilities	123.66	290.45
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	816.36	677.67
(ii) Trade payables		
(A) Total outstanding dues of Micro enterprises and Small Enterprises	48.17	40.12
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	127.60	620.53
(iii) Other financial liabilities	1.93	6.23
(b) Other current liabilities	51.17	74.06
(c) Short term Provision	55.27	18.30
(d) Current tax liabilities (Net)	-	14.53
Total current liabilities	1,100.50	1,451.45
Total Equity and liabilities	2,595.03	3,245.80

Date : May 29th, 2024
Place : Vadodara



For Link Pharma Chem Limited

Satish G. Thakur
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

Website : www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LIMITED
CIN : L24230GJ1984PLC007540

STATEMENT OF AUDITED CASH FLOW FOR THE YEAR ENDED 31ST MARCH 2024

(Rs in Lakhs)

Particulars	For the year ended March 31, 2024	For the year ended March 31, 2023
	(Audited)	(Audited)
A. Cash Flow From Operating Activities		
Net profit before taxation	(191.58)	88.63
Adjustments For :		
Depreciation and amortization expense	103.42	92.28
Net gain on sale of investments	(0.18)	(14.63)
Fair valuation of Investments through FVTPL	(49.21)	40.69
Bad debts written off	1.56	39.52
Provision for Doubtful Debts	4.00	2.00
Loss / (profit) on Sale of Property, Plant & Equipment	(7.89)	0.00
Dividend Income	(1.61)	(8.08)
Interest income	(4.76)	(3.25)
Finance cost	87.20	76.10
Net Adjustments	132.54	224.63
Operating Profit Before Working Capital Changes	(59.04)	313.26
Adjustments For :		
(Increase)/Decrease in inventories	604.20	(749.28)
(Increase)/Decrease in trade receivables	(157.73)	132.00
(Increase)/Decrease in financial assets	5.95	(0.11)
(Increase)/Decrease in other assets	131.72	109.51
Increase/(Decrease) in trade and other payables	(490.92)	64.56
Working Capital Changes	93.22	(443.33)
Cash Generated From Operations	34.18	(130.07)
Taxes Paid (Net)	(36.98)	(40.62)
Net Cash From Operating Activities (A)	(2.80)	(170.69)
B. Cash Flow From Investing Activities		
Purchase of property, plant & equipment	(95.03)	(89.29)
Proceeds from sale of property, plant & equipment	12.00	0.00
Purchase of investments	(23.76)	(341.90)
Proceeds from sale of investments	144.11	403.83
Dividend Income	1.61	8.08
(Increase)/Decrease in bank deposits	(4.94)	5.02
Interest received	6.53	6.76
Net Cash Used in Investing Activities (B)	40.52	(7.50)
C. Cash Flow From Financing Activities		
Proceeds from Long term borrowings	-	53.00
Repayment of long term borrowings	(156.38)	(136.58)
Proceeds/(repayment) of short term borrowings (Net)	202.88	320.47
Finance cost paid	(87.20)	(76.10)
Net Cash Used In Financing Activities (C)	(40.70)	160.79
Net (decrease) / Increase In Cash and Cash Equivalents (A+B+C)	(2.97)	(17.40)
Cash and Cash Equivalents at Beginning of Year	9.39	26.79
Cash and Cash Equivalents at the End of Year	6.42	9.39

Date : May 29th, 2024
Place : Vadodara



For Link Pharma Chem Limited
Satish G. Thakur
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

Website : www.linkpharmachem.co.in

Independent Auditor's Report on Audited Quarterly Financial Results and Year to Date Results of Link Pharma Chem Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS OF
LINK PHARMA CHEM LIMITED

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of financial results of Link Pharma Chem Ltd (the company) for quarter and year ended 31st March, 2024 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India of the net profit/(Loss) and other comprehensive income/(loss) and other financial information for the quarter/ year ended 31st March, 2024.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those SAs are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI



Management's Responsibilities for the Financial Results

The statement has been prepared on the basis of the financial statements. The Company's Management and Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Management and Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Management and Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the financial results made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.




We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other matter

- a. The Statement includes the results for the quarter ended 31st March, 2024 being the balancing figures between the audited figures in respect of full financial year ended 31st March, 2024 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For CNK & Associates, LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036



Pareen Shah

Partner

Membership No. 125011

Place: Vadodara

Date: 29th May, 2024

UDIN: 24125011BKEQWL3202





Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

DECLARATION

Declaration pursuant to Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on Audit Report with unmodified opinion

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and as per SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that, M/s. CNK & Associates LLP, Chartered Accountants, (Firm Registration No. 101961W/W-100036), Statutory Auditor of the Company have issued an Audit Report with unmodified opinion and contains no qualification or adverse remark on the Standalone Audited Financial Results of the Company for the financial year ended on March 31, 2024.

For Link Pharma Chem Limited



Date: 29.05.2024

Place: Vadodara

Satish G. Thakur
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490

E-Mail: linkpharmacs@gmail.com

CIN: L24230GJ1984PLC007540

Website: www.linkpharmachem.co.in

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Secretarial Auditor

Sr. No.	Disclosure Requirement	Details
01.	Name of Firm	Vijay Bhatt & Co., Practicing Company Secretaries, Vadodara
02.	Reason for change, viz. appointment, resignation, removal, death or otherwise	Re-appointment
03.	Date of appointment / cessation (as applicable) & term of appointment	Date of re-appointment: 29.05.2024 Term of re-appointment: To act as Secretarial Auditor and conduct secretarial audit for the financial year 2024-25.
04.	Brief profile	Mr. Vijay J Bhatt is the Proprietor of M/s. Vijay Bhatt & Co., Vadodara. He has been whole time practicing Company Secretary for more than 27 years. He is qualified as B. Com (Hons), LL. B (spl) and fellow member of Institute of Company Secretaries of India (ICSI).
05.	Disclosure of relationships between Directors (in case of appointment of a director)	No relationship with directors.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in

Details required under Regulation 30 of SEBI (LODR) Regulations, 2015
Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Internal Auditor

Sr. No.	Disclosure Requirement	Details
01.	Name of Firm	Dipak Rajpara & Co., Chartered Accountant, Vadodara
02.	Reason for change, viz. appointment, resignation, removal, death or otherwise	Re-appointment
03.	Date of appointment / cessation (as applicable) & term of appointment	Date of re-appointment: 29.05.2024 Term of re-appointment: To act as Internal Auditor and conduct Internal audit for the financial year 2024-25.
04.	Brief profile	Mr. Dipak Rajpara is qualified Chartered Accountant and Cost and Management Accountant since 2006. He is Proprietor of Dipak Rajpara & Co., Vadodara. He is having experience of 15 years in areas of Accounting, Taxation, finance, Auditing and Advisory Services.
05.	Disclosure of relationships between Directors (in case of appointment of a director)	No relationship with directors.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in